Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

3.1%

4 terminated out of 129 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

9%

11 trials in Phase 3/4

Results Transparency

36%

10 of 28 completed with results

Key Signals

10 with results88% success

Data Visualizations

Phase Distribution

79Total
Not Applicable (30)
Early P 1 (2)
P 1 (15)
P 2 (21)
P 3 (5)
P 4 (6)

Trial Status

Recruiting49
Not Yet Recruiting30
Completed28
Active Not Recruiting6
Unknown5
Terminated4

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (129)

Showing 20 of 20 trials
NCT06619990Phase 1RecruitingPrimary

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT07564895CompletedPrimary

Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab.

NCT07564609Enrolling By Invitation

the REMONO-CD and the REMONO-UC Studies

NCT07350577Phase 1Active Not RecruitingPrimary

Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants

NCT07389161Not ApplicableRecruiting

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

NCT06095596Not ApplicableRecruitingPrimary

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

NCT06992453Not ApplicableNot Yet Recruiting

Multi-omics Dissection of Gut Microbiome Engraftment During FMT

NCT07415044Phase 2RecruitingPrimary

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07524244Not ApplicableRecruiting

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07248644Phase 4Not Yet RecruitingPrimary

Immunosuppressant Discontinuation in Elderly Patients With Ulcerative Colitis And Long-term Remission

NCT07374471Phase 1RecruitingPrimary

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07271069RecruitingPrimary

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07507513Phase 2Not Yet RecruitingPrimary

The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC

NCT07427017Phase 2RecruitingPrimary

Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

NCT07431983RecruitingPrimary

Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

NCT07237516RecruitingPrimary

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07472309CompletedPrimary

Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis

NCT07113522Phase 2Recruiting

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

NCT07300553Phase 2Recruiting

Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease

NCT07459686Not Yet RecruitingPrimary

An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis

Scroll to load more

Research Network

Activity Timeline